Cellular therapy against public neoantigens.

Area of Science:

• Oncology
• Immunology
• Cancer immunotherapy

Background:

• Neoantigen-targeted therapies often rely on personalized vaccines.
• Acute myeloid leukemia (AML) frequently harbors mutations in nucleophosmin 1 (NPM1).

Purpose of the Study:

• To develop a cellular immunotherapy targeting a "public" neoantigen derived from NPM1.
• To investigate the potential of targeting NPM1 mutations in AML.

Main Methods:

• Utilized reverse immunology to predict neoepitopes derived from NPM1 (ΔNPM1).
• Biochemically confirmed predicted neoepitopes.
• Generated high-avidity T cell clones and retrovirally transduced T cell populations.

Main Results:

• Developed T cell therapies capable of killing NPM1-mutated AML cells.
• Demonstrated the efficacy of targeting a public neoantigen in AML.

Conclusions:

• This study presents a generalizable approach for adoptive cellular therapy.
• The strategy can be applied to target other tumors expressing public neoantigens.